MX2019005185A - Metodos para tratar las carcinomas uroteliales del tracto superior. - Google Patents

Metodos para tratar las carcinomas uroteliales del tracto superior.

Info

Publication number
MX2019005185A
MX2019005185A MX2019005185A MX2019005185A MX2019005185A MX 2019005185 A MX2019005185 A MX 2019005185A MX 2019005185 A MX2019005185 A MX 2019005185A MX 2019005185 A MX2019005185 A MX 2019005185A MX 2019005185 A MX2019005185 A MX 2019005185A
Authority
MX
Mexico
Prior art keywords
methods
ureter
balloon
catheter
renal pelvis
Prior art date
Application number
MX2019005185A
Other languages
English (en)
Inventor
V Betageri Guru
G Oefelein Michael
Venkatesan Natarajan
Original Assignee
Univ Western Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Western Health Sciences filed Critical Univ Western Health Sciences
Publication of MX2019005185A publication Critical patent/MX2019005185A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1078—Urinary tract
    • A61M2210/1089—Urethra

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a métodos para administrar de manera local un agente quimioterapéutico a un carcinoma urotelial del tracto superior (UTUC). Los métodos implican colocar un catéter con balón que tiene un canal de trabajo y un balón dentro del uréter/pelvis renal a través de acceso retrógrado o anterógrado; inflar el balón del catéter para obstruir temporalmente el uréter; infusionar (instilar) una formulación liposomal que incluye un agente quimioterapéutico dentro del canal de trabajo del catéter; y permitir que la formulación liposomal infusionada permanezca en el uréter y/o pelvis renal durante un tiempo suficiente para permitir que al menos una parte de la formulación liposomal se adhiera a la pared urotelial. En los métodos de la invención, al menos una parte de la formulación con agente quimioterapéutico infusionado se adhiere a la pared urotelial mientras es instalada y permanece en el uréter y/o pelvis renal. Los métodos descritos se pueden realizar como una terapia adyuvante con respecto a otros métodos para tratar UTUC, tales como extirpación o ablación ureteroscópica del tumor.
MX2019005185A 2016-11-11 2017-11-10 Metodos para tratar las carcinomas uroteliales del tracto superior. MX2019005185A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662421055P 2016-11-11 2016-11-11
PCT/US2017/061047 WO2018089759A1 (en) 2016-11-11 2017-11-10 Methods of treating upper tract urothelial carcinomas

Publications (1)

Publication Number Publication Date
MX2019005185A true MX2019005185A (es) 2019-07-01

Family

ID=62109985

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005185A MX2019005185A (es) 2016-11-11 2017-11-10 Metodos para tratar las carcinomas uroteliales del tracto superior.

Country Status (16)

Country Link
US (1) US20190343763A1 (es)
EP (1) EP3538074B1 (es)
JP (1) JP7096553B2 (es)
KR (1) KR20190084284A (es)
CN (1) CN110167533A (es)
AU (1) AU2017358049B2 (es)
BR (1) BR112019009616A2 (es)
CA (1) CA3043620A1 (es)
CL (1) CL2019001262A1 (es)
CO (1) CO2019005881A2 (es)
CR (1) CR20190274A (es)
EA (1) EA201991143A1 (es)
MX (1) MX2019005185A (es)
NZ (1) NZ753214A (es)
PE (1) PE20191653A1 (es)
WO (1) WO2018089759A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6697541B2 (ja) * 2016-01-07 2020-05-20 ウエスタン ユニバーシティ オブ ヘルス サイエンシーズ 膀胱癌処置のための処方物
GB201900389D0 (en) 2019-01-11 2019-02-27 Queens Univ Of Belfast Solvent and water-free lipid-based nanoparticles and their methods of manufacture

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759058B1 (en) 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
EA007481B1 (ru) * 2001-09-24 2006-10-27 Тоск, Инк. Цисплатиновые составы пониженной токсичности и способы их применения
JP5645340B2 (ja) * 2003-10-15 2014-12-24 メディゲーネ アクチエンゲゼルシャフトＭｅｄｉＧｅｎｅ ＡＧ 活性成分を含有するカチオンリポソームの投与方法
US20090171241A1 (en) 2006-03-03 2009-07-02 Garcia Maurice M System and method for urinary tract cell collection, diagnosis, and chemotherapy
EP2090305A4 (en) * 2006-12-08 2012-12-26 Katayama Chemical Ind Co Ltd LIPOSOME ENCAPSULATING HIGH-CONCENTRATION <O> AMINE </ O> COMPLEX, AND PROCESS FOR PRODUCING THE SAME
EP2146692A1 (en) 2007-03-19 2010-01-27 Fresenius Kabi Oncology Limited Proliposomal and liposomal compositions
CN101322689B (zh) * 2007-06-11 2012-10-24 江苏先声药物研究有限公司 一种多西他赛长循环脂质体及其冻干粉针的制备方法
GEP201706754B (en) * 2012-05-09 2017-10-25 Univ Western Health Sciences Proliposomal testosterone formulations
US20140172118A1 (en) 2012-12-19 2014-06-19 Cook Medical Technologies Llc Bioactive Compositions, Bioactive Eluting Devices and Methods of Use Thereof
US20160175559A1 (en) * 2014-12-23 2016-06-23 Cook Medical Technologies Llc Medical Devices for Delivery and Retention of Bioactive Agents
WO2016134066A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof
EP3274044B1 (en) * 2015-03-26 2023-03-01 Vensica Medical Ltd. Ultrasonic urinary bladder drug delivery
US10888640B2 (en) * 2015-04-24 2021-01-12 Urotronic, Inc. Drug coated balloon catheters for nonvascular strictures
JP6249987B2 (ja) 2015-05-13 2017-12-20 ルトニックス，インコーポレーテッド 医療用具のための薬物放出コーティング
JP6697541B2 (ja) 2016-01-07 2020-05-20 ウエスタン ユニバーシティ オブ ヘルス サイエンシーズ 膀胱癌処置のための処方物

Also Published As

Publication number Publication date
CA3043620A1 (en) 2018-05-17
BR112019009616A2 (pt) 2019-08-13
EA201991143A1 (ru) 2019-10-31
EP3538074A4 (en) 2020-06-24
JP2019534305A (ja) 2019-11-28
WO2018089759A1 (en) 2018-05-17
AU2017358049A1 (en) 2019-05-30
AU2017358049B2 (en) 2023-11-09
CO2019005881A2 (es) 2019-08-30
EP3538074A1 (en) 2019-09-18
KR20190084284A (ko) 2019-07-16
CL2019001262A1 (es) 2019-07-26
CN110167533A (zh) 2019-08-23
EP3538074B1 (en) 2023-07-26
PE20191653A1 (es) 2019-11-07
US20190343763A1 (en) 2019-11-14
CR20190274A (es) 2019-07-29
NZ753214A (en) 2022-02-25
JP7096553B2 (ja) 2022-07-06

Similar Documents

Publication Publication Date Title
WO2015186003A3 (en) Methods and devices for treating pulmonary edema
MX2020011581A (es) Catéter de globo.
MX2016016070A (es) Introductor y guia de cateter con aguja tangencial subretinal.
PH12017550063A1 (en) Combination therapies for treating cancers
MX346726B (es) Sistemas de tratamiento criogénico.
CA2902713C (en) Method and apparatus for drug delivery to a target site
WO2012156914A3 (en) Microporous balloon catheter, delivery system, and methods of manufacture and use
NZ753214A (en) Methods of treating upper tract urothelial carcinomas
MX341823B (es) Metodo y aparato para tratamiento criogenico de una cavidad o lumen corporal.
BR112016028641A2 (pt) ?método para tratar câncer?
WO2019051274A3 (en) DEVICES FOR THE TREATMENT OF BRONCHOPULMONARY TUMORS
JP2019510075A5 (es)
WO2018064588A3 (en) Tert immunogenic compositions and methods of treatment using the same
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
EA201990976A1 (ru) Новый способ профилактического лечения непроизвольной потери массы
JOP20200124A1 (ar) طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
MX2017004004A (es) Metodo y dispositivo para cateterizacion transradial sin funda.
Ohlmann et al. Comment re: Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3 Trial. Lancet Oncol 2015; 16: 76-86
MX2019007729A (es) Reducción del daño de la quimioterapia y aumento de las tasas de destrucción de cáncer usando radiación entremezclada de baja dosis.
MY197942A (en) Adjuvant therapy for use in prostate cancer treatment
Zaghloul In Regard to Reddy et al
NZ742470A (en) Combination therapy for cancer
EAU-ESTRO-ESUR-SIOG et al. Prostate cancer and the John West effect
Li et al. Counterpoints: which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer
Aigner et al. Six-Years Disease-Free Survival after Isolated Hypoxic Pelvic Perfusion with Chemofiltration for Advanced Cervical Carcinoma